RHY 8.57% 7.6¢ rhythm biosciences limited

Ann: ColoSTAT abstracts accepted at 2023 ASCO Annual Meeting, page-13

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 280 Posts.
    lightbulb Created with Sketch. 95
    With each opportunity Rhythm has for exposure, it's also important to remember the significance of clinical trial results for Colostat. They have essentially discovered the 'holly grail' for CRC mass population screening after all! Accurate low cost blood test for early detection of CRC, developed over a 14 year period by CSIRO, 35% more effective than the current screening method which has low participation rates due to handling of one's own poo, GPs can add to standard panel of patient blood tests (same blood draw), fits existing equipment in pathology labs...

    In a landscape of 2000 abstracts available to 40,000 cancer professionals, it's sure to be of particular interest.
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.